Hypercalcemia Treatment Global Market Report 2025

The hypercalcemia treatment market size has grown rapidly in recent years. It will grow from $16.44 billion in 2024 to $18.34 billion in 2025 at a compound annual growth rate (CAGR) of 11.5%. The growth during the historic period can be attributed to increasing awareness of hypercalcemia, a growing geriatric population, a rise in cancer cases, greater disease awareness, and the increasing prevalence of parathyroid disorders.

The hypercalcemia treatment market size is expected to see rapid growth in the next few years. It will grow to $28.31 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The growth during the forecast period can be attributed to the rising prevalence of chronic renal disease, the increasing number of patients with hypertension, higher investment in developing novel medications, greater awareness and patient empowerment, and government initiatives. Key trends in the forecast period include enhanced diagnostic tools and techniques, advancements in treatment options, the development of innovative drugs, and increased collaborations among healthcare providers.

The increasing prevalence of parathyroid disorders is expected to drive the expansion of the hypercalcemia treatment market. Parathyroid disorders affect the parathyroid glands, which regulate calcium levels in the body through the production of parathyroid hormone (PTH). Several factors contribute to the rising prevalence of these disorders, including an aging population, increased awareness, improved diagnostic capabilities, and a growing incidence of conditions such as primary hyperparathyroidism and chronic kidney disease. Hypercalcemia treatment plays a crucial role in managing parathyroid disorders by controlling elevated calcium levels, preventing complications such as kidney stones and bone loss, and maintaining overall metabolic balance. For example, according to the National Institute of Health (NIH), a US-based government agency, hypoparathyroidism in the United States is estimated to affect 6.4 to 37 per 100,000 person-years, with 75% of cases resulting from complications of thyroidectomy or head and neck surgery. As a result, the increasing prevalence of parathyroid disorders is fueling the growth of the hypercalcemia treatment market.

Leading companies in the hypercalcemia treatment market are focusing on developing innovative solutions, such as phosphate binders, to enhance calcium and phosphorus regulation and improve treatment outcomes. Phosphate binders are medications that prevent phosphate absorption in the digestive tract and are commonly used to manage high phosphate levels in patients with kidney disease or hypercalcemia. For instance, in May 2024, Strides Pharma Science Limited, an India-based pharmaceutical company, received approval from the United States Food and Drug Administration (FDA) for its Sevelamer Carbonate Tablets, 800 mg. These tablets effectively manage hyperphosphatemia in patients with chronic kidney disease by binding dietary phosphate and preventing its absorption, helping to maintain bone health and reduce cardiovascular risks associated with elevated phosphate levels.

In December 2024, Teijin Pharma Limited, a Japan-based pharmaceutical company, partnered with Ascendis Pharma A/S to introduce innovative prodrug technology for hypoparathyroidism treatment. This collaboration enables Teijin to utilize advanced prodrug technology that provides sustained PTH levels, potentially offering a more effective and convenient treatment option compared to existing therapies. Ascendis Pharma A/S, a Denmark-based company, specializes in developing innovative prodrugs for treating hypoparathyroidism in adults.

Major players in the hypercalcemia treatment market are Pfizer Inc., Roche Holding AG, AbbVie Inc., AstraZeneca plc, Novartis AG, GSK plc, Eli Lilly and Company, Amgen Inc., Merck KGaA, Fresenius Medical Care AG & Co. KGaA, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Ipsen SA, Kyowa Kirin Co. Ltd., Hikma Pharmaceuticals plc, Endo International plc, OPKO Health Inc., Ferring Pharmaceuticals A/S, Rockwell Medical Inc., Strides Pharma Science Limited.

North America was the largest region in the hypercalcemia treatment market in 2024. The regions covered in hypercalcemia treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hypercalcemia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Hypercalcemia treatment involves the medical management of elevated calcium levels in the blood caused by conditions such as hyperparathyroidism or malignancies. Treatment options include hydration, diuretics, bisphosphonates, and calcitonin to lower calcium levels and prevent complications. It is utilized in both emergency and long-term care settings to prevent kidney damage, neurological issues, and cardiac dysfunction.

The primary drug types for hypercalcemia treatment include bisphosphonates, calcitonin, glucocorticoids, denosumab, calcimimetics, and others. Bisphosphonates are a class of medications that treat bone diseases by inhibiting osteoclast activity, reducing bone breakdown. The treatment is indicated for conditions such as primary hyperparathyroidism, hypercalcemia of malignancy, and others. These medications are distributed through various channels, including hospitals, retail pharmacies, and online pharmacies, and are used by multiple end-users, such as hospitals and clinics.

The hypercalcemia treatment market research report is one of a series of new reports that provides hypercalcemia treatment market statistics, including the hypercalcemia treatment industry global market size, regional shares, competitors with the hypercalcemia treatment market share, detailed hypercalcemia treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the hypercalcemia treatment industry. This hypercalcemia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hypercalcemia treatment market consists of revenues earned by entities through services such as surgical treatment, dietary modifications, and bisphosphonates. The market value includes the value of related goods sold by the service provider or included within the service offering. The hypercalcemia treatment market also includes sales of metabolic testing devices, body composition analyzers, and wearable fitness trackers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.